These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34495376)

  • 1. Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers.
    Pistrosch F; Matschke JB; Schipp D; Schipp B; Henkel E; Weigmann I; Sradnick J; Bornstein SR; Birkenfeld AL; Hanefeld M
    Diabetologia; 2021 Dec; 64(12):2701-2712. PubMed ID: 34495376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Connolly SJ; Eikelboom JW; Bosch J; Dagenais G; Dyal L; Lanas F; Metsarinne K; O'Donnell M; Dans AL; Ha JW; Parkhomenko AN; Avezum AA; Lonn E; Lisheng L; Torp-Pedersen C; Widimsky P; Maggioni AP; Felix C; Keltai K; Hori M; Yusoff K; Guzik TJ; Bhatt DL; Branch KRH; Cook Bruns N; Berkowitz SD; Anand SS; Varigos JD; Fox KAA; Yusuf S;
    Lancet; 2018 Jan; 391(10117):205-218. PubMed ID: 29132879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy.
    Tantry U; Cummings C; Mackrell P; Gonze M; Ulloa K; Bafford R; Rout A; Sukhi A; Gurbel P
    Future Cardiol; 2020 Mar; 16(2):69-75. PubMed ID: 32129681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition.
    Ramacciotti E; Weitz JI
    Thromb Res; 2019 Dec; 184():44-49. PubMed ID: 31706067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
    Eikelboom JW; Connolly SJ; Bosch J; Dagenais GR; Hart RG; Shestakovska O; Diaz R; Alings M; Lonn EM; Anand SS; Widimsky P; Hori M; Avezum A; Piegas LS; Branch KRH; Probstfield J; Bhatt DL; Zhu J; Liang Y; Maggioni AP; Lopez-Jaramillo P; O'Donnell M; Kakkar AK; Fox KAA; Parkhomenko AN; Ertl G; Störk S; Keltai M; Ryden L; Pogosova N; Dans AL; Lanas F; Commerford PJ; Torp-Pedersen C; Guzik TJ; Verhamme PB; Vinereanu D; Kim JH; Tonkin AM; Lewis BS; Felix C; Yusoff K; Steg PG; Metsarinne KP; Cook Bruns N; Misselwitz F; Chen E; Leong D; Yusuf S;
    N Engl J Med; 2017 Oct; 377(14):1319-1330. PubMed ID: 28844192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial.
    Bhatt DL; Eikelboom JW; Connolly SJ; Steg PG; Anand SS; Verma S; Branch KRH; Probstfield J; Bosch J; Shestakovska O; Szarek M; Maggioni AP; Widimský P; Avezum A; Diaz R; Lewis BS; Berkowitz SD; Fox KAA; Ryden L; Yusuf S;
    Circulation; 2020 Jun; 141(23):1841-1854. PubMed ID: 32223318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement.
    De Backer O; Dangas GD; Jilaihawi H; Leipsic JA; Terkelsen CJ; Makkar R; Kini AS; Veien KT; Abdel-Wahab M; Kim WK; Balan P; Van Mieghem N; Mathiassen ON; Jeger RV; Arnold M; Mehran R; Guimarães AHC; Nørgaard BL; Kofoed KF; Blanke P; Windecker S; Søndergaard L;
    N Engl J Med; 2020 Jan; 382(2):130-139. PubMed ID: 31733182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban in Peripheral Artery Disease after Revascularization.
    Bonaca MP; Bauersachs RM; Anand SS; Debus ES; Nehler MR; Patel MR; Fanelli F; Capell WH; Diao L; Jaeger N; Hess CN; Pap AF; Kittelson JM; Gudz I; Mátyás L; Krievins DK; Diaz R; Brodmann M; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR
    N Engl J Med; 2020 May; 382(21):1994-2004. PubMed ID: 32222135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels.
    Parker WAE; Schulte C; Barwari T; Phoenix F; Pearson SM; Mayr M; Grant PJ; Storey RF; Ajjan RA
    Cardiovasc Diabetol; 2020 Jan; 19(1):3. PubMed ID: 31910903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS.
    Bhagirath VC; Eikelboom JW; Anand SS
    Future Cardiol; 2018 Nov; 14(6):443-453. PubMed ID: 30417662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating dickkopf-1 in diabetes mellitus: association with platelet activation and effects of improved metabolic control and low-dose aspirin.
    Lattanzio S; Santilli F; Liani R; Vazzana N; Ueland T; Di Fulvio P; Formoso G; Consoli A; Aukrust P; Davì G
    J Am Heart Assoc; 2014 Jul; 3(4):. PubMed ID: 25037197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.
    Kasner SE; Swaminathan B; Lavados P; Sharma M; Muir K; Veltkamp R; Ameriso SF; Endres M; Lutsep H; Messé SR; Spence JD; Nedeltechev K; Perera K; Santo G; Olavarria V; Lindgren A; Bangdiwala S; Shoamanesh A; Berkowitz SD; Mundl H; Connolly SJ; Hart RG;
    Lancet Neurol; 2018 Dec; 17(12):1053-1060. PubMed ID: 30274772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin.
    Prandoni P; Lensing AWA; Prins MH; Gebel M; Pap AF; Homering M; Bauersachs R; Beyer-Westendorf J; Bounameaux H; Cohen AT; Davidson BL; van Bellen B; Verhamme P; Wells PS; Yuan Z; Levitan B; Weitz JI
    Thromb Res; 2018 Aug; 168():121-129. PubMed ID: 30064683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microparticle Shedding by Erythrocytes, Monocytes and Vascular Smooth Muscular Cells Is Reduced by Aspirin in Diabetic Patients.
    Chiva-Blanch G; Suades R; Padró T; Vilahur G; Peña E; Ybarra J; Pou JM; Badimon L
    Rev Esp Cardiol (Engl Ed); 2016 Jul; 69(7):672-80. PubMed ID: 27103451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease.
    Coleman CI; Kharat AA; Bookhart B; Baker WL
    Curr Med Res Opin; 2022 Jan; 38(1):27-34. PubMed ID: 34641745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased concentrations of platelet- and endothelial-derived microparticles in patients with myocardial infarction and reduced renal function- a descriptive study.
    Mörtberg J; Lundwall K; Mobarrez F; Wallén H; Jacobson SH; Spaak J
    BMC Nephrol; 2019 Mar; 20(1):71. PubMed ID: 30823870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement.
    Dangas GD; Tijssen JGP; Wöhrle J; Søndergaard L; Gilard M; Möllmann H; Makkar RR; Herrmann HC; Giustino G; Baldus S; De Backer O; Guimarães AHC; Gullestad L; Kini A; von Lewinski D; Mack M; Moreno R; Schäfer U; Seeger J; Tchétché D; Thomitzek K; Valgimigli M; Vranckx P; Welsh RC; Wildgoose P; Volkl AA; Zazula A; van Amsterdam RGM; Mehran R; Windecker S;
    N Engl J Med; 2020 Jan; 382(2):120-129. PubMed ID: 31733180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The protective effect of rivaroxaban with or without aspirin on inflammation, oxidative stress, and platelet reactivity in isoproterenol-induced cardiac injury in rats.
    Abedalqader NN; Rababa'h AM; Ababneh M
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Feb; 396(2):337-351. PubMed ID: 36334131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.